1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
4.2.2 Increasing Number of Clinical Studies and Availability of Funding for Gene Therapy Development
4.2.3 Potential Applications in Novel Drug Delivery Approaches
4.3 Market Restraints
4.3.1 High Cost of Gene Therapies
4.3.2 Challenges in Viral Vector Manufacturing Capacity
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Plasmid DNA
5.1.2 Viral Vector
5.1.3 Non-viral Vector
5.2 By Application
5.2.1 Cancer
5.2.2 Genetic Disorder
5.2.3 Infectious Disease
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Oxford Biomedica
6.1.2 Cognate BioServices Inc. (Cobra Biologics)
6.1.3 Cell and Gene Therapy Catapult
6.1.4 FinVector Vision Therapies
6.1.5 Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
6.1.6 MassBiologics
6.1.7 SIRION Biotech
6.1.8 Merck KGaA Inc.
6.1.9 Thermo Fisher Scientific
6.1.10 Uniqure NV
6.1.11 Catalent, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Oxford Biomedica
- Cognate BioServices Inc. (Cobra Biologics)
- Cell and Gene Therapy Catapult
- FinVector Vision Therapies
- Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
- MassBiologics
- SIRION Biotech
- Merck KGaA Inc.
- Thermo Fisher Scientific
- Uniqure NV
- Catalent, Inc.